Subscribe To Our Free Newsletter |
Cipla rallies 4% on US FDA approval to market Lanreotide injection
The approval for the generic version of Lanreotide Acetate is in line with Cipla's growth strategy in the complex product segment and will strengthen Cipla's position in the US market.